Beyond abiraterone

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893 - 917; http://dx.doi.org/10.1002/ijc.25516; PMID: 21351269
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61:1079 - 92; http://dx.doi.org/10.1016/j.eururo.2012.02.054; PMID: 22424666
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59:572 - 83; http://dx.doi.org/10.1016/j.eururo.2011.01.025; PMID: 21315502
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502 - 12; http://dx.doi.org/10.1056/NEJMoa040720; PMID: 15470213
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242 - 5; http://dx.doi.org/10.1200/JCO.2007.12.4008; PMID: 18182665
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513 - 20; http://dx.doi.org/10.1056/NEJMoa041318; PMID: 15470214
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147 - 54; http://dx.doi.org/10.1016/S0140-6736(10)61389-X; PMID: 20888992
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr., Saad F, et al, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995 - 2005; http://dx.doi.org/10.1056/NEJMoa1014618; PMID: 21612468
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, et al, COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983 - 92; http://dx.doi.org/10.1016/S1470-2045(12)70379-0; PMID: 22995653
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza PL, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138 - 48; http://dx.doi.org/10.1056/NEJMoa1209096; PMID: 23228172
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore N, De Souza PL, et al. Long-term safety and efficacy analysis of abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer without prior chemotherapy (COU-AA-302). J Clin Oncol 2013; 31; suppl; abstr 5009 PMID: 24002508
   PubMedGoogle Scholar
• Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10:981 - 91; http://dx.doi.org/10.1016/S1470-2045(09)70229-3; PMID: 19796750
   PubMed Web of Science ®Google Scholar
• Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011; 17:3876 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-10-2815; PMID: 21680543
   PubMed Web of Science ®Google Scholar
• Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008; 617:223 - 34; http://dx.doi.org/10.1007/978-0-387-69080-3_21; PMID: 18497046
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815 - 25; http://dx.doi.org/10.1158/0008-5472.CAN-05-4000; PMID: 16510604
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009; 27:251 - 7; http://dx.doi.org/10.1016/j.urolonc.2009.03.016; PMID: 19414113
   PubMed Web of Science ®Google Scholar
• Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab 2009; 4:417 - 22; http://dx.doi.org/10.1586/eem.09.34; PMID: 20228873
   PubMedGoogle Scholar
• Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69:16 - 22; http://dx.doi.org/10.1158/0008-5472.CAN-08-2764; PMID: 19117982
   PubMed Web of Science ®Google Scholar
• Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487:239 - 43; http://dx.doi.org/10.1038/nature11125; PMID: 22722839
   PubMed Web of Science ®Google Scholar
• Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15:841 - 9; http://dx.doi.org/10.1677/ERC-08-0084; PMID: 18667687
   PubMed Web of Science ®Google Scholar
• Lamont KR, Tindall DJ. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011; 25:897 - 907; http://dx.doi.org/10.1210/me.2010-0469; PMID: 21436259
   PubMed Web of Science ®Google Scholar
• Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol 2013; 40:244 - 58; http://dx.doi.org/10.1053/j.seminoncol.2013.04.001; PMID: 23806491
   PubMed Web of Science ®Google Scholar
• Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007; 31:1246 - 55; http://dx.doi.org/10.1097/PAS.0b013e31802f5d33; PMID: 17667550
   PubMed Web of Science ®Google Scholar
• Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, Doubinskaia I, van der Meer R, Hayward SW, Eischen CM, et al. Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest 2012; 122:1907 - 19; http://dx.doi.org/10.1172/JCI58540; PMID: 22484818
   PubMed Web of Science ®Google Scholar
• Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69:8141 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-09-0919; PMID: 19808968
   PubMed Web of Science ®Google Scholar
• Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J, Scher HI. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010; 105:462 - 7; http://dx.doi.org/10.1111/j.1464-410X.2009.08747.x; PMID: 19624594
   PubMed Web of Science ®Google Scholar
• Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487:239 - 43; http://dx.doi.org/10.1038/nature11125; PMID: 22722839
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68:5469 - 77; http://dx.doi.org/10.1158/0008-5472.CAN-08-0594; PMID: 18593950
   PubMed Web of Science ®Google Scholar
• Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 2012; 287:8571 - 83; http://dx.doi.org/10.1074/jbc.M111.325290; PMID: 22275373
   PubMed Web of Science ®Google Scholar
• Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010; 21:315 - 24; http://dx.doi.org/10.1016/j.tem.2010.01.002; PMID: 20138542
   PubMed Web of Science ®Google Scholar
• Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J 2011; 30:3885 - 94; http://dx.doi.org/10.1038/emboj.2011.340; PMID: 21934649
   PubMed Web of Science ®Google Scholar
• Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011; 30:3962 - 76; http://dx.doi.org/10.1038/emboj.2011.328; PMID: 21915096
   PubMed Web of Science ®Google Scholar
• Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 2012; 180:848 - 61; http://dx.doi.org/10.1016/j.ajpath.2011.10.021; PMID: 22138582
   PubMed Web of Science ®Google Scholar
• Gallucci M, Merola R, Leonardo C, De Carli P, Farsetti A, Sentinelli S, Sperduti I, Mottolese M, Carlini P, Vico E, et al. Genetic profile identification in clinically localized prostate carcinoma. Urol Oncol 2009; 27:502 - 8; http://dx.doi.org/10.1016/j.urolonc.2008.04.008; PMID: 18534873
   PubMed Web of Science ®Google Scholar
• Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010; 13:311 - 5; http://dx.doi.org/10.1038/pcan.2010.31; PMID: 20820186
   PubMed Web of Science ®Google Scholar
• Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68:3584 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-07-6154; PMID: 18483239
   PubMed Web of Science ®Google Scholar
• Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A 2009; 106:12465 - 70; http://dx.doi.org/10.1073/pnas.0905931106; PMID: 19592505
   PubMed Web of Science ®Google Scholar
• Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26:4596 - 9; http://dx.doi.org/10.1038/sj.onc.1210237; PMID: 17237811
   PubMed Web of Science ®Google Scholar
• Dumas L, Payne H, Chowdhury S. The evolution of antiandrogens: MDV3100 comes of age. Expert Rev Anticancer Ther 2012; 12:131 - 3; http://dx.doi.org/10.1586/era.11.210; PMID: 22316360
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787 - 90; http://dx.doi.org/10.1126/science.1168175; PMID: 19359544
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, et al, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437 - 46; http://dx.doi.org/10.1016/S0140-6736(10)60172-9; PMID: 20398925
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al, AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187 - 97; http://dx.doi.org/10.1056/NEJMoa1207506; PMID: 22894553
   PubMed Web of Science ®Google Scholar
• Miller K, Scher HI, Fizazi K, Basch EM, Sternberg CN, Hirmand M, et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration resistant prostate cancer (mCRPC) following docetaxel-based therapy: results from the AFFIRM study. J Clin Oncol 2013; 31 suppl 6; abstr 17
   Google Scholar
• Scher HI, Fizazi K, Saad Chi KN, Taplin ME, Sternberg CN, et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide, an androgen receptor inhibitor. J Clin Oncol 2013; 31 suppl 6; abstr 6
   Google Scholar
• Golshayan AR, Antonarakis ES. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013; 8:27 - 35; PMID: 23589709
   PubMedGoogle Scholar
• Smith MR, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Efficacy and safety of enzalutamide monotherapy in hormone-naïve prostate cancer. J Clin Oncol 2013; 31 suppl; abstr 5001
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72:1494 - 503; http://dx.doi.org/10.1158/0008-5472.CAN-11-3948; PMID: 22266222
   PubMed Web of Science ®Google Scholar
• Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71:480 - 8; http://dx.doi.org/10.1002/pros.21263; PMID: 20878947
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Danila DC, Morris MJ, Slovin SF, Steinbrecher JE, Arauz G, et al. Phase I/II safety and pharmacokinetic study of ARN-509 in patients with metastatic castration-resistant prostate cancer patients: phase I results of a Prostate Cancer Clinical Trials Consortium study. J Clin Oncol 2012; 30 suppl 5; abstr 43
   Google Scholar
• Rathkopf DE, Antonarakis ES, Shore ND, Tutrone R, Alumkal JJ, Ryan CJ, et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCPRC). J Clin Oncol 2013; 31:suppl 6; abstr 48
   Web of Science ®Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore N, Liu G, et al. ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2013; 31:suppl 6; abstr 7
   Google Scholar
• Kaku T, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, Hara T, Yamaoka M, Kusaka M, Okuda T, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19:6383 - 99; http://dx.doi.org/10.1016/j.bmc.2011.08.066; PMID: 21978946
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29:3651 - 8; http://dx.doi.org/10.1200/JCO.2011.35.2005; PMID: 21859989
   PubMed Web of Science ®Google Scholar
• Agus DB, Stadler WM, Shevrin DH, Hart L, MacVicar GR, Hamid O, et al. Safety, efficacy and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer: updated data form a phase I/II study. J Clin Oncol 2012; 30 suppl 5; abstr 98
   Google Scholar
• George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, et al. Safety and activity of the investigational agent orteronel without prednisone in men with nonmetastatic castration resistant prostate cancer and rising prostate-specific antigen: updated results of a phase II study. J Clin Oncol 2012; X suppl; abstr 4549
   Google Scholar
• Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 2008; 7:2348 - 57; http://dx.doi.org/10.1158/1535-7163.MCT-08-0230; PMID: 18723482
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Eisenberger MA, Rettig M, Chu F, Pili R, Stephenson J, et al. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer. J Clin Oncol 2012; 30 suppl; abstr 4665
   Google Scholar
• Jacoby DB, Williams M. Differential effects of galeterone, abiraterone, orteronel and ketoconazole on CYP 17 and steroidogenesis. J Clin Oncol 2013; 3 suppl 6; abstr 184
   Google Scholar
• Massard C, James N, Culine S, Jones R, Vuorela A, Mustonen M, et al. ARADES trial: a first-in-man, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients with progressive metastatic castration resistant prostate cancer. Ann Oncol 2012; 23 suppl 9
   Google Scholar
• Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011; 60:897 - 904; http://dx.doi.org/10.1016/j.eururo.2011.07.011; PMID: 21802835
   PubMed Web of Science ®Google Scholar
• Attard G, De Bono JS, Li W, Molina A, Griffin TW, San Kheoh T, et al. ERG rearrangements and association with clinical outcome in patients receiving abiraterone acetate: Results from the COU-AA-302 study in chemotherapy-naïve metastatic castration-resistant prostate cancer. J Clin Oncol 2013; 31 suppl; abstr 5004
   Google Scholar
• de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-0872; PMID: 18829513
   PubMed Web of Science ®Google Scholar
• Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents. Curr Opin Urol 2012; 22:190 - 6; http://dx.doi.org/10.1097/MOU.0b013e3283519b58; PMID: 22328019
   PubMed Web of Science ®Google Scholar
• Nakai Y, Nonomura N. Inflammation and prostate carcinogenesis. Int J Urol 2013; 20:150 - 60; http://dx.doi.org/10.1111/j.1442-2042.2012.03101.x; PMID: 22852773
   PubMed Web of Science ®Google Scholar